Device Trial Radar · NCT07207122
Effects of Transcranial Focused Ultrasound Stimulation (tFUS) on Neurological and Cognitive Outcomes in Parkinson's Disease
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Oct 8, 2025
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Sanmai Technologies PBC dba SanmaiNot on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 3, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 22 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a pilot randomized, sham-controlled, double-blind, multi-center study evaluating the safety and preliminary effectiveness of the Gen0Bh Transcranial Focused Ultrasound System for the treatment of motor symptoms in individuals with idiopathic Parkinson's disease.
Conditions
- Parkinson Disease
Interventions
Gen0Bh Transcranial Focused Ultrasound System (Active)Device
The investigational Gen0Bh system delivers noninvasive, transcranial focused ultrasound to modulate neural activity in the bilateral globus pallidus. Stimulation parameters, including frequency, intensity, and duty cycle, are pre-specified and controlled by the device software. Treatments are administered by trained study personnel in a clinical setting over 20 sessions across approximately 4 to 6 weeks.
Gen0Bh Transcranial Focused Ultrasound System (Sham)Device
The sham configuration uses the same device platform and mimics all procedural aspects of active treatment, including acoustic coupling, device setup, and session duration, without delivering therapeutic ultrasound energy to the target region. This approach is designed to maintain participant and assessor blinding.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in MDS-UPDRS Part III Total Score (OFF Medication State)Time frame: Baseline up to 6 weeks
- Incidence of Serious Adverse Device Events (SADEs)Time frame: Baseline up to 6 weeks
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
University of Arizona
Tucson, Arizona · Recruiting
The Regenesis Project
Santa Monica, California · Recruiting
UF - McKnight Brain Institute
Gainesville, Florida · Recruiting
1 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.